Lifeforce, the world’s largest longevity-focused medical platform, has announced a groundbreaking partnership with Toku, a health tech innovator using artificial intelligence to analyze retinal images for real-time insights into biological age and cardiovascular risk. This collaboration marks a significant milestone in preventive healthcare by integrating Toku’s BioAge™ wellness product—and eventually its FDA Breakthrough Device-designated CLAiR™ technology—into Lifeforce’s nationwide longevity platform. The combined solution enables individuals to convert routine eye exams into highly actionable health screenings, offering a seamless bridge between early risk detection and expert-led intervention.

The primary goal of this partnership is to empower individuals with meaningful, non-invasive insights into their biological aging and cardiovascular health—and to immediately connect them to evidence-based longevity protocols. Toku’s AI algorithms extract critical data from a single retinal image, allowing for rapid assessment of vascular health and biological age. Through Lifeforce’s comprehensive system, users can take action on those insights via at-home diagnostics, personalized care plans, and support from certified health coaches and board-certified physicians. Together, the two platforms offer a closed-loop, data-driven system for early intervention and long-term health optimization.

This partnership is especially timely as aging populations and lifestyle-related chronic diseases continue to place pressure on healthcare systems. By leveraging the ubiquity of eye exams and integrating cutting-edge AI analysis, Lifeforce and Toku are making early detection and preventive medicine more accessible and personalized than ever. As CLAiR™ moves toward FDA approval in 2026, the partnership is poised to reshape how consumers and clinicians monitor, manage, and reduce cardiovascular and aging-related risks—setting a new benchmark in proactive, precision longevity care.